Enhancing the expression and rhythmic amplitude of Bmal1 through interface Schottky barrier, in conjunction with strategically timing its administration, holds immense promise for advancing the future treatment of AT and the development of innovative therapeutic approaches targeting circadian rhythms. Here, BMAL1 is linked to ataxia telangiectasia.